Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 455 |
|
|||||
| News | - | ||||||
| Day High | 4.23 | Low High |
|||||
| Day Low | 4.01 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| SAB Biotherapeutics Inc | SABS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.39 | -8.86% | 4.01 | 09:54:36 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 4.01 | 4.01 | 4.23 | 4.40 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 6 | 455 | $ 4.01 | $ 1,825 | - | 4.00 - 11.90 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 10:00:05 | 1 | $ 4.23 | USD |
SAB Biotherapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 36.99M | 9.23M | - | 2.24M | -42.19M | -4.57 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
SAB Biotherapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SABS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.34 | 4.7062 | 4.01 | 4.40 | 1,430 | -0.33 | -7.60% |
| 1 Month | 4.22 | 4.94 | 4.01 | 4.51 | 3,476 | -0.21 | -4.98% |
| 3 Months | 5.8183 | 6.30 | 4.00 | 5.13 | 13,944 | -1.81 | -31.08% |
| 6 Months | 9.50 | 10.50 | 4.00 | 7.78 | 37,072 | -5.49 | -57.79% |
| 1 Year | 7.40 | 11.90 | 4.00 | 8.45 | 98,919 | -3.39 | -45.81% |
| 3 Years | 78.00 | 120.90 | 3.657 | 25.80 | 235,225 | -73.99 | -94.86% |
| 5 Years | 78.00 | 120.90 | 3.657 | 25.80 | 235,225 | -73.99 | -94.86% |
SAB Biotherapeutics Description
| SAB Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing fully human, multi-targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The company's lead asset, SAB-142, targets Type-1 diabetes (T1D) with a disease-modifying therapeutic approach that aims at changing the treatment paradigm by delaying onset and potentially preventing disease progression. |
